Genomic Vision raises €4 million
This article was originally published in Scrip
Executive Summary
Genomic Vision has secured €4 million to fund its in-house R&D, automation and strengthen its collaborative programmes with partners. The French drug discovery and diagnostics firm will use its nanotechnology for DNA analysis in cancer and acute diseases. Genomic's Molecular Combing technology tests the efficacy of lead compounds by studying DNA replication in proliferating cancer cells. The series B round included new investor Vesalius BioCapital and existing investor Societe Generale Asset Management Alternative Investments. Since its inception in 2004, Genomic has raised €6 million.